MSFrontier

MS-OPT Version 1.3 dated 23/05/18

A double-blind, randomised, placebo-controlled single-site study of high dose simvastatin treatment for secondary progressive multiple sclerosis: impact on vascular perfusion and oxidative damage
Phase 2Progressive MS2017-003008-30

What was tested

Treatment tested

  • Simvastatin

    HMG-CoA reductase inhibitor

What it measured

Main measures

  • To establish whether simvastatin has an effect on cerebral blood flow in SPMS up to 22 weeks using arterial spin labelling MRI.

    MRI lesions

Other measures (1)

  • • To establish whether ASL and AOSLO measurements of blood flow are useful correlates for cerebral blood flow measurement on and off treatment. This will be supported by a questionnaire investigating factors that influence brain perfusion.

Loading reviews and guidelines…

Related trials

  • MS-OPT

    Phase 2 · Completed

    Results posted, no main test reported

  • MS-STAT2

    Phase 3 · Completed

    Missed its main goal

  • MS-STAT

    Phase 2 · Completed

    Met its main goal

History

  1. In scope changed from true to false

  1. Started

    May 2018

Assembled by software from public sources and not checked by people. Each record links to its source. Report an error